131 related articles for article (PubMed ID: 36855965)
1. Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: A population-based study.
Kuijper SC; Pape M; Vissers PAJ; Jeene PM; Kouwenhoven EA; Haj Mohammad N; Ruurda JP; Sosef MN; Verhoeven RHA; van Laarhoven HWM
Int J Cancer; 2023 Jul; 153(1):33-43. PubMed ID: 36855965
[TBL] [Abstract][Full Text] [Related]
2. Beyond Median Overall Survival: Estimating Trends for Multiple Survival Scenarios in Patients With Metastatic Esophagogastric Cancer.
Pape M; Kuijper SC; Vissers PAJ; Beerepoot LV; Creemers GJ; van Laarhoven HWM; Verhoeven RHA
J Natl Compr Canc Netw; 2022 Dec; 20(12):1321-1329.e4. PubMed ID: 36509070
[TBL] [Abstract][Full Text] [Related]
3. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data.
Hamers PAH; Elferink MAG; Stellato RK; Punt CJA; May AM; Koopman M; Vink GR
Int J Cancer; 2021 Jan; 148(2):296-306. PubMed ID: 32638384
[TBL] [Abstract][Full Text] [Related]
4. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
Kiely BE; Soon YY; Tattersall MH; Stockler MR
J Clin Oncol; 2011 Feb; 29(4):456-63. PubMed ID: 21189397
[TBL] [Abstract][Full Text] [Related]
5. Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
Vasista A; Stockler M; Martin A; Pavlakis N; Sjoquist K; Goldstein D; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Nott L; Snow S; Burge M; Harris D; Jonker D; Chua YJ; Epstein R; Bonaventura A; Kiely B
Oncologist; 2019 Nov; 24(11):e1102-e1107. PubMed ID: 30936377
[TBL] [Abstract][Full Text] [Related]
6. Trends in treatment and overall survival among patients with proximal esophageal cancer.
de Vos-Geelen J; Geurts SM; van Putten M; Valkenburg-van Iersel LB; Grabsch HI; Haj Mohammad N; Hoebers FJ; Hoge CV; Jeene PM; de Jong EJ; van Laarhoven HW; Rozema T; Slingerland M; Tjan-Heijnen VC; Nieuwenhuijzen GA; Lemmens VE
World J Gastroenterol; 2019 Dec; 25(47):6835-6846. PubMed ID: 31885424
[TBL] [Abstract][Full Text] [Related]
7. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
[TBL] [Abstract][Full Text] [Related]
8. Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials.
Kiely BE; Alam M; Blinman P; Tattersall MH; Stockler MR
Lung Cancer; 2012 Sep; 77(3):537-44. PubMed ID: 22609149
[TBL] [Abstract][Full Text] [Related]
9. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials.
West TA; Kiely BE; Stockler MR
Eur J Cancer; 2014 Jul; 50(11):1916-24. PubMed ID: 24825113
[TBL] [Abstract][Full Text] [Related]
10. SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer.
van den Boorn HG; Abu-Hanna A; Haj Mohammad N; Hulshof MCCM; Gisbertz SS; Klarenbeek BR; Slingerland M; Beerepoot LV; Rozema T; Sprangers MAG; Verhoeven RHA; van Oijen MGH; Zwinderman KH; van Laarhoven HWM
J Natl Compr Canc Netw; 2021 Apr; 19(4):403-410. PubMed ID: 33636694
[TBL] [Abstract][Full Text] [Related]
11. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.
van der Kaaij RT; Koemans WJ; van Putten M; Snaebjornsson P; Luijten JCHBM; van Dieren JM; Cats A; Lemmens VEPP; Verhoeven RHA; van Sandick JW
Eur J Cancer; 2020 May; 130():23-31. PubMed ID: 32171106
[TBL] [Abstract][Full Text] [Related]
12. Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival.
Koëter M; van Putten M; Verhoeven RHA; Lemmens VEPP; Nieuwenhuijzen GAP
Acta Oncol; 2018 Sep; 57(9):1192-1200. PubMed ID: 29528262
[TBL] [Abstract][Full Text] [Related]
13. Synchronous primary esophageal squamous cell carcinoma and gastric adenocarcinoma: analysis of 41 cases treated in a single institution.
Li X; Lin S; Zhang Y; Wang H
Sci Rep; 2015 Aug; 5():13335. PubMed ID: 26290280
[TBL] [Abstract][Full Text] [Related]
14. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
15. Early diagnosis and management of esophageal and gastric cancer.
Lang GD; Konda VJ
Minerva Gastroenterol Dietol; 2013 Dec; 59(4):357-76. PubMed ID: 24212354
[TBL] [Abstract][Full Text] [Related]
16. Increased resection rates and survival among patients aged 75 years and older with esophageal cancer: a Dutch nationwide population-based study.
Faiz Z; Lemmens VE; Siersema PD; Nieuwenhuijzen GA; Wouters MW; Rozema T; Coebergh JW; Wijnhoven BP
World J Surg; 2012 Dec; 36(12):2872-8. PubMed ID: 22965535
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
18. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
19. Impact of multidisciplinary tumor board discussion on palliation of patients with esophageal or gastro-esophageal junction cancer: a population-based study.
Vermeulen BD; Bruggeman L; Bac DJ; Schrauwen RWM; Epping LSM; Scheffer RCH; Tan ACITL; Groenen MJM; Verhoeven RHA; Siersema PD
Acta Oncol; 2020 Apr; 59(4):410-416. PubMed ID: 32067535
[No Abstract] [Full Text] [Related]
20. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
